Fig. 6: ARAC improves survival of mice bearing metastatic lung tumors.
From: Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
a C57BL/6 mice were injected with 200,000 LLC-JSP cells intravenously. After 3 days, mice were treated with saline, free drugs (i.p., at 1x dose: 2.5 µg volasertib and 20 µg PD-L1 and 5x dose: 12.5 µg volasertib and 100 µg PD-L1 antibody), ARAC (i.v., containing 2.5 µg volasertib and 20 µg PD-L1), or ARAC + anti-CD8 (200 μg i.p. twice weekly). Treatments were administered every 3 days for a total of 4 doses. b, c Kaplan–Meier Survival curve. *P = 0.0120, **P = 0.0033, ***P = 0.0009, ns – not significant (Log-rank Mantel–Cox test). d Mouse weight change post first treatment; data presented as mean ± SEM. Source data are provided as a Source Data file.
